Unknown

Dataset Information

0

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.


ABSTRACT:

Background

EGFR tyrosine kinase inhibitors (TKIs) induce cytolysis and release of tumour proteins, which can stimulate antigen-specific T cells. The safety and efficacy of durvalumab and gefitinib in combination for TKI-naive patients with advanced EGFRm NSCLC was evaluated.

Methods

This Phase 1 open-label, multicentre trial (NCT02088112) was conducted in 56 patients with NSCLC. Dose expansion permitted TKI-naive patients, primarily with activating L858R or Ex19del EGFRm. Arms 1 + 1a received concurrent therapy; Arm 2 received 4 weeks of gefitinib induction followed by concurrent therapy.

Results

From dose escalation, the recommended dose of durvalumab was 10 mg/kg Q2W with 250 mg QD gefitinib. Pharmacokinetics were as expected, consistent with inhibition of soluble PD-L1 and no treatment-emergent immunogenicity. In dose expansion, 35% of patients had elevated liver enzymes leading to drug discontinuation. In Arms 1 + 1a, objective response rate was 63.3% (95% CI: 43.9-80.1), median progression-free survival (PFS) was 10.1 months (95% CI: 5.5-15.2) and median response duration was 9.2 months (95% CI: 3.7-14.0).

Conclusions

Durvalumab and gefitinib in combination had higher toxicity than either agent alone. No significant increase in PFS was detected compared with historical controls. Therefore, concurrent PD-L1 inhibitors with gefitinib should be generally avoided in TKI-naive patients with EGFRm NSCLC.

SUBMITTER: Creelan BC 

PROVIDER: S-EPMC7852511 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC8298067 | biostudies-literature
| S-EPMC10789945 | biostudies-literature
| S-EPMC10372607 | biostudies-literature
| S-EPMC6614728 | biostudies-literature
2022-02-11 | E-MTAB-11404 | biostudies-arrayexpress
| S-EPMC6000013 | biostudies-other
| S-EPMC5650459 | biostudies-literature
| S-EPMC8274031 | biostudies-literature
| S-EPMC11238182 | biostudies-literature
| S-EPMC8233144 | biostudies-literature